<PAGE>
As filed with the Securities and Exchange Commission on November 3, 2000
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): October 26, 2000
AMGEN INC.
(Exact name of Registrant as specified in its charter)
Delaware 95-3540776
(State or other jurisdiction of 000-12477 (I.R.S. Employer
incorporation or organization) (Commission File No.) Identification No.)
__________________
One Amgen Center Drive
Thousand Oaks, California 91320-1799
(Address of Principal Executive Offices including Zip Code)
(805) 447-1000
(Registrant's Telephone Number, Including Area Code)
================================================================================
<PAGE>
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On October 26, 2000, the Registrant publicly disseminated a press release
announcing its third quarter financial results.
The foregoing description is qualified in its entirety by reference to the
following document, which is incorporated herein by reference: the Registrant's
Press Release dated October 26, 2000, a copy of which is attached hereto as
Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements
Not applicable.
(b) Pro Forma Financial Information
Not applicable.
(c) Exhibits.
99.1 Registrant's Press Release dated October 26, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: November 3, 2000 AMGEN INC.
By: /s/ Kathryn E. Falberg
------------------------------
Name: Kathryn E. Falberg
Title: Senior Vice President, Finance
and Corporate Development
and Chief Financial Officer
